Capstone swings to operating income of USD 432,000 in Q2 FY26; net sales rise 67% to USD 21.48 million

Reuters2026/08/12 11:43

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Capstone Therapeutics posted Q2 net sales of USD 21.48 million, up 67% year over year.
Net loss widened to USD 1.38 million; operating income swung to USD 432,000 from an operating loss.
Gross profit climbed to USD 6 million; gross margin rose 3.5 percentage points to 27.9%.
Interest and other expense widened to USD 1.96 million; SG&A increased 63% to USD 5.51 million.
Management cited acquisition contributions, a USD 438,000 tariff refund, and higher-margin Carolina Stone mix as key drivers.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Capstone Therapeutics Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-027150), on August 12, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Capstone swings to operating income of USD 432,000 in Q2 FY26; net sales rise 67% to USD 21.48 million

You may also like

Crypto prices